Improve suspension culture expansion, transfection, and protein production in DG44 cells

Several new kits for streamlining protein generation in CHO DG44 (dhfr¯) cells are now available. The cells, media, and transfection reagents are designed for suspension culture, reducing the time needed to get to expressed protein. You'll easily create high density CHO suspension cultures, efficiently transfect in suspension, and express protein; all in chemically defined, animal component-free media systems.

Sku Name Size Price Qty
10743011 CD CHO Medium (1X) 500 mL USD 46.00
10743029 1X CD CHO Medium, liquid 1,000 mL USD 84.00
12052098 CHO-S-SFM II, with hypoxanthine and thymidine 1,000 mL USD 87.00
12052114 CHO-S-SFM II, with hypoxanthine and thymidine 500 mL USD 50.00
12490001 CD CHO AGT™ Medium 100 L USD 3,860.00
12490003 CD CHO AGT™ Medium 10 kg USD 9,710.00
12490017 CD CHO AGT™ Medium 1 L USD 63.00
12490025 CD CHO AGT™ Medium 10 L USD 562.00
12610010 CD DG44 Medium 1,000 mL USD 87.00
12651014 Gibco® FreeStyle™ CHO Expression Medium 1,000 mL USD 84.00
12651022 Gibco® FreeStyle™ CHO Expression Medium 6 x 1,000 mL USD 481.00
12681011 1X CD OptiCHO™ Medium, liquid 1,000 mL USD 76.00
12681029 CD OptiCHO™ Medium (1X) 6 x 1,000 mL USD 434.00
31033020 CHO-S-SFM II (without hypoxanthine or thymidine) 500 mL USD 67.00
A1122201 CD OptiCHO™ AGT™ Medium 100 L USD 4,300.00
A1122204 CD OptiCHO™ AGT™ Medium 1 L USD 68.00
A1122205 CD OptiCHO™ AGT™ Medium 10 L USD 620.00

Inherent selection with dhfr¯cells

DG44 cells, dihydrofolate reductase deficient (dhfr¯) derivates of Chinese Hamster Ovary (CHO) cells, are routinely used to establish cell lines for production of recombinant protein. They were developed by Dr. Chasin at Columbia University using gamma rays to eliminate the entire dhfr locus. In non-mutated cells, dhfr is an essential enzyme for de novo synthesis of glycine, purines, and thymidylate. This allows dhfr to be used as a dominant selectable marker and a gene amplifier for the expression of proteins in dhfr¯ cell lines. The dhfr¯ mutation in DG44 cells is stable and irreversible, which makes it a suitable mammalian cell line for production of recombinant proteins. GIBCO™ offers a complete system for the growth and expansion of DG44 (dhfr¯) cells in suspension, including:

  • DG44 Cells and Media Kit—fully characterized DG44 cells pre-adapted to chemically defined, animal origin component-free media for growth
  • DG44 Transfection Kit—a complete kit optimized for high-efficiency transfection of CD44 cells in suspension
  • Growth Optimization Kits—two kits that allow you to conveniently optimize growth conditions for your specific applications

Improve suspension culture expansion, transfection, and protein production in DG44 cells. Several new kits for streamlining protein generation in CHO DG44 (dhfr¯) cells are now available. The cells, media, and transfection reagents are designed for suspension culture, reducing the time needed to get to expressed protein. You'll easily create high density CHO suspension cultures, efficiently transfect in suspension, and express protein; all in chemically defined, animal component-free media systems.

Optimize Growth with the DG44 Cells and Media Kit

The DG44 Cells and Media Kit is optimized for suspension growth of CHO-DG44 (dhfr¯) cells and expression of recombinant proteins in suspension culture. This kit provides characterized DG44 cells selected for superior cell growth and transfection efficiencies and CD DG44 Medium, an animal origin component-free, chemically defined formulation that contains no proteins, hydrosylates, or components of unknown composition. CD DG44 Medium is supplemented with necessary components for the growth and maintenance of dhfr¯ cell lines, including hypoxanthine and thymidine. GIBCO™ DG44 Cells are pre-adapted to this medium and grow in suspension
culture with densities of ~2-3 × 106 cells/ml. DG44 cells transfected with a plasmid carrying dhfr as a marker can be grown in this medium without the need for any selectable drug agents, providing a great advantage for the production of diagnostic or therapeutic recombinant proteins.